Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?

Biomedicinsk Institut

Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?

Publikation: Bidrag til tidsskrift › Leder › Forskning › fagfællebedømt

Standard

Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? / Holst, Jens Juul.

I: The Lancet, Bind 394, Nr. 10192, 2019, s. 4-6.

Publikation: Bidrag til tidsskrift › Leder › Forskning › fagfællebedømt

Harvard

Holst, JJ 2019, 'Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?', The Lancet, bind 394, nr. 10192, s. 4-6. https://doi.org/10.1016/S0140-6736(19)31350-9

APA

Holst, J. J. (2019). Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? The Lancet, 394(10192), 4-6. https://doi.org/10.1016/S0140-6736(19)31350-9

Vancouver

Holst JJ. Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? The Lancet. 2019;394(10192):4-6. https://doi.org/10.1016/S0140-6736(19)31350-9

Author

Holst, Jens Juul. / Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?. I: The Lancet. 2019 ; Bind 394, Nr. 10192. s. 4-6.

Bibtex

@article{7a05639db93249f5ba8627597a941d90,

title = "Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?",

author = "Holst, {Jens Juul}",

year = "2019",

doi = "10.1016/S0140-6736(19)31350-9",

language = "English",

volume = "394",

pages = "4--6",

journal = "The Lancet",

issn = "0140-6736",

publisher = "TheLancet Publishing Group",

number = "10192",